# Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

> **NCT00272493** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 48 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** Hepatitis B virus vaccine with GM-CSF adjuvant
- **BIOLOGICAL:** Hepatitis B virus vaccine

## Key facts

- **NCT ID:** NCT00272493
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2007-11
- **Final completion:** 2008-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272493, "Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT00272493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*